Compare MYRG & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYRG | GPCR |
|---|---|---|
| Founded | 1891 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 2008 | 2023 |
| Metric | MYRG | GPCR |
|---|---|---|
| Price | $334.41 | $43.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $262.43 | $103.17 |
| AVG Volume (30 Days) | 238.8K | ★ 902.6K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 311.48 | N/A |
| EPS | ★ 7.53 | N/A |
| Revenue | ★ $1,531,169,000.00 | N/A |
| Revenue This Year | $11.87 | N/A |
| Revenue Next Year | $8.48 | N/A |
| P/E Ratio | $46.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $117.18 | $15.80 |
| 52 Week High | $349.15 | $94.90 |
| Indicator | MYRG | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.78 | 31.20 |
| Support Level | $251.81 | $42.72 |
| Resistance Level | N/A | $57.23 |
| Average True Range (ATR) | 10.86 | 2.95 |
| MACD | 1.00 | -0.47 |
| Stochastic Oscillator | 68.43 | 0.69 |
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution networks and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.